Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > 1次抗体

Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767) (MB613013)

Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767)
Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767)
価格(USD):
スペック:
  • 20ug
  • 50ug
  • 100ug
  • 1mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号MB613013
説明
Anti-Mouse CD223/LAG3 Nanobody (SAA0767) [SAA0767] (MB613013) is a alpaca monoclonal antibody detecting CD223 in ELISA, FCM. Suitable for Mouse.
Highlights
  • ●Flow Cytometry — Validated for flow cytometry applications.
種反応性Mouse
アプリケーションELISA, FCM
宿主種Alpaca
クローン性Monoclonal
アイソタイプVHH-8His-Cys-tag
クローンIDSAA0767
ターゲット CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3
エンドトキシンレベル < 10 EU/mg
純度 >95% as determined by SDS-PAGE.
精製 Purified by Nickel column.
アクセッション番号 Q61790
形態 Liquid
保存バッファー 0.01M PBS pH 7.4.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

製品使用情報
アプリケーション 希釈
ELISA 1:2000-1:20000
安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
背景

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~56 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Workman, CJ. et al. (2002) European journal of immunology 32, 2255-63. PMID: 12209638
2. Workman, CJ. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 169, 5392-5. PMID: 12421911
3. Workman, CJ. et al. (2003) European journal of immunology 33, 970-9. PMID: 12672063
4. Workman, CJ. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 172, 5450-5. PMID: 15100286
5. Workman, CJ. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 174, 688-95. PMID: 15634887
6. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966
7. Maruhashi, T. et al. (2022) Immunity 55, 912-924.e8. PMID: 35413245
8. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082
9. Silberstein, JL. et al. (2024) Proceedings of the National Academy of Sciences of the United States of America 121, e2310866121. PMID: 38483996
10. Ming, Q. et al. (2024) Nature communications 15, 7513. PMID: 39209860
注意事項 For research use only.
イメージ
  • Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767)

    SDS-PAGE

    SDS-PAGE for Anti-Mouse CD223/LAG3 Nanobody (SAA0767)

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト